13th Annual Outsourcing in Clinical Trials UK & Ireland 2026

Creating a collaborative environment where pharma & biotech leaders can find solutions to current challenges through innovations and partnerships

9 - 10

June

2026
  • Hilton Park Lane, London, UK
  • Complimentary
  • Why attend?
  • Agenda
  • Advisory Board
  • Speakers
  • Plan Your Visit
  • Event Gallery
  • 2026 Sponsors
  • Media Centre
  • Why partner?
  • Resources
  • Contact Us
close

2026 Sponsors Include:

Back

Company Information

Simply sourcing comparators – we offer a unique blend of small company flexibility and speed, backed with the large-scale buying power of the Orifarm Group, which is one of the largest pharmaceutical suppliers in Europe. With over €1.4B products sold in 2021 and more than 4,000 unique product lines sourced on a monthly basis, we have unparalleled access to “out of market” and manufacturer direct buying capability, both in the US and Europe.

Company website: www.Orifarm-CTS.com

Company Website

To learn more, please visit our website - www.Orifarm-CTS.com

Next Sponsor
Back

Company Information

Imagine a paediatric-specific engagement platform, fully co-designed with children and child life specialists. The Little Journey app helps to reduce anxiety before, during and after paediatric clinical trial visits by educating and preparing children and families using engaging, age-tailored personalised multimedia that can be accessed anywhere at any time.

Company Website

To learn more, please visit our website - https://www.littlejourney.health/

Next Sponsor
Back

Company Information

Cytel Inc. www.cytel.com is a leading provider of clinical research services and trial design and analysis software primarily for the biopharmaceutical and medical device development markets.

Cytel pioneered the statistical and computational science of adaptive clinical trials and has designed more validated adaptive trials than any other service provider.

Company Website

To learn more, please visit our website - http://www.cytel.com

Next Sponsor
Back

Company Information

Syneos Health (Nasdaq:SYNH*) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together more than 21,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together, we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to lifeTM visit SyneosHealth.com. 

Company Website

To learn more, please visit our website - www.SyneosHealth.com

Next Sponsor
Back

Company Information

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 35,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.

Company Website

To learn more, please visit our website - https://www.medidata.com

Next Sponsor
Back

Company Information

Founded in 2015 Teckro provides solutions to simplify and modernize clinical research for leading pharmaceutical and emerging biotech companies. To date, Teckro manages more than 100 clinical trials and is used by more than 11,800 active study sites around the world. Teckro employs more than 100 staff across its global headquarters in Limerick, Ireland, engineering excellence hub in Dublin, Ireland and its US-based office in Nashville, Tennessee. Visit www.teckro.com for more information.

 

Company Website

To learn more, please visit our website - http://www.teckro.com/

Next Sponsor
Back

Company Information

Medicover Integrated Clinical Services is a unique clinical research organization with 25 years of experience.

We offer Patient Recruitment services through our own Clinical Research Network in Central and Eastern Europe with comprehensive Global Central Lab Services and access to over 8,000 tests from routine to advanced diagnostics including genetics, biomarkers, PK and PD, and PBMC isolation in more than 120 laboratories in Europe and India.

Company Website

To learn more, please visit our website - https://medicover-mics.com/

Next Sponsor
Back

Company Information

Optimapharm is a globally operating, leading, mid-sized, full-service CRO aiming to deliver new therapies to improve and save patients’ lives.
With 26 strategically located offices, Optimapharm is giving unrivalled access to Patients and Investigators worldwide.
Optimapharm conducts phase I – IV studies in all therapeutic areas. With very strong operational teams, Optimapharm has a reputation for excellence delivery in all projects, including rescue studies.

Company Website

To learn more, please visit our website - https://optimapharm.eu/

Next Sponsor
Back

Company Information

Greenphire is the industry leader of clinical payment technology, designed to improve the way research professionals work. We leverage our proprietary payments platform and workflow automation to help clients improve operational efficiency, reduce costs, mitigate regulatory risks, improve the patient and site experience and produce quantifiable results that improve clinical operations and strategic planning.

Company Website

To learn more, please visit our website - http://greenphire.com/

Next Sponsor
Back

Company Information

ESMS Global provides specialist support related to Clinical Trials and Medical Information. Our services include a Global Emergency Unblinding Service, Clinical Trials Direct to Patient Helpline, Serious Breach Reporting Service, and a Medical Information Helpline, all available 24/7, across the globe, in 45 languages.

Company Website

To learn more, please visit our website - www.esmsglobal.com

Next Sponsor
Back

Company Information

At Trilogy, medical writing is our passion. As specialists in clinical regulatory documentation, we provide a service that is more than just writing. We proactively plan, coordinate and write clinical documents to meet timelines, with a readability that reduces the time for review and approval.

Company Website

To learn more, please visit our website - https://www.trilogywriting.com/

Next Sponsor
Back

Company Information

TFS HealthScience is a global Contract Research Organization (CRO) partnering with biotechnology and pharmaceutical companies throughout their entire clinical development journey. Bringing together nearly 700 professionals, we deliver tailored clinical research services in more than 40 countries. TFS supports customers with comprehensive solutions including full clinical development services, strategic and flexible resourcing. In partnership, we build solution-driven teams of experienced professionals working together for a healthier future. Our mission is to bring treatments to patients faster. For more information, please visit www.tfscro.com.

Company Website

To learn more, please visit our website - www.tfscro.com.

Next Sponsor
Back

Company Information

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 6,000 people across 44 countries.

Company Website

To learn more, please visit our website - http://www.medpace.com/

Next Sponsor
Back

Company Information

Almac Group is a global leader in providing a range of expert services and support across the drug development lifecycle.

We are trusted experts in R&D, diagnostic services, API manufacture, formulation development, clinical trial supply services and technologies through to commercial-scale manufacture and distribution.

We are recognised as an industry leader in client service, providing understanding, experience and knowledge to our clients as we work together to advance human health.

Almac is trusted by the leading global biopharma companies to provide crucial services across their drug development projects. In the last 5 years alone, we have contributed to over 50% of all FDA approved New Molecular Entities (NMEs) and are currently supporting 30% of EU approved /pre-registered Gene therapy products.

A privately owned organisation, Almac has grown organically over the past five decades, employing over 7,700 highly skilled employees across 18 facilities in Europe, North America, and Asia. Learn more about us at https://www.almacgroup.com/

Company Website

To learn more, please visit our website - https://www.almacgroup.com

Next Sponsor
Back

Company Information

At Viedoc, we design engaging software that modernizes clinical research so that necessary treatments can reach the people who need them faster. We believe in life and science, in people, and in our collective power to change the world and build a healthier future. That unmatched driving force is what pushes us to innovate, accelerate and improve every aspect of modern clinical studies.

Company Website

To learn more, please visit our website - www.viedoc.com

Next Sponsor
Back

Company Information

Suvoda is a global clinical trial technology company specializing in complex, life-sustaining studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease. Founded in 2013 by experts in eClinical technologies, Suvoda empowers clinical trial professionals to manage the most urgent moments in the most urgent trials through advanced software solutions delivered on a single platform. Headquartered outside Philadelphia, Suvoda also maintains offices in Portland, OR, Barcelona, Spain, Bucharest and Iasi, Romania, and Tokyo, Japan. The company’s Net Promoter Score (NPS) consistently exceeds the technology industry average, contributing to the company being selected by trial sponsors and CROs to support more than 1,000 trials across 80 countries.

Company Website

To learn more, please visit our website - https://www.suvoda.com/

Next Sponsor
Back

Company Information

ClinChoice is a leading global full & functional service CRO, renowned for its exceptional product development and lifecycle management capabilities across the pharmaceutical, biotechnology, medical device, and consumer health sectors. With three decades of proven expertise and outstanding results, we excel in delivering top-tier services.

Our deep regulatory expertise, clinical trial execution, and robust pharmacovigilance and biometrics capabilities position us as a trusted partner in global markets. ClinChoice proudly maintains a strong presence across the Americas, Europe, and Asia-Pacific, ensuring comprehensive support for our clients worldwide.

https://clinchoice.com/

Next Sponsor
Back

Company Information

CMIC Group, founded as Japan’s first CRO over 30 years ago, is now the largest clinical CRO in Japan with a global presence. Our services span non-clinical studies, clinical trial management, GMP manufacturing, regulatory consulting, and sales/marketing solutions. We facilitate market entry in Japan, offer leading clinical trial expertise in APAC region, and bridge drug development between the US and Japan. With 7,000+ employees and 24 global sites, we’re your comprehensive partner in the pharmaceutical, biotech, and medical device sectors.

Company Website

To learn more, please visit our website - https://en.cmicgroup.com/

Next Sponsor
Back

Company Information

B. Braun specialises in manufacturing market leading infusion therapy products, many of which are supplied into clinical trials. With presence in over 64 countries around the world, we work closely with our partners to select solutions that fit with the individual clinical trial requirements.

For more information, please visit:

Company Website

To learn more, please visit our website - bbraun.co.uk/en/products-and-therapies/bbraun-industrial-business.html

Next Sponsor

    Why attend?

    We are delighted to welcome you to 13th annual Outsourcing in Clinical Trials UK and Ireland.

    This is a great opportunity to get together and network face to face, hear from our expert speaker line-up and discuss the latest innovations and regulatory updates in the industry.

    This exclusive event brings together attendees from established pharma, large and small, alongside biopharmaceutical companies and gives opportunity to dive into the operational challenges and innovations in clinical development found within the UK & Ireland region.

    This year will also focus on government initiatives for UK growth and opportunities within the clinical trial landscape.

    We look forward to you joining us!

     

    WHAT TO EXPECT FOR 2026?

    This exclusive event brings together attendees from established pharma, large and small, alongside with biopharmaceutical companies and gives opportunity to dive into the operational challenges and innovations in clinical development found within the UK & Ireland region.

    200+

    Attendees

    		50+

    Exhibitors

    		40+

    Speakers
    200+

    Attendees

    		50+

    Exhibitors
    40+

    Speakers

    Testimonials

    See What It's All About

    Agenda

    • 9 Jun 2026
    • 10 Jun 2026
    Expand All

    Streams

    Stream one

    STREAM A: UK Clinical Trial Landscape Strategy

    Stream two

    STREAM B: Clinical Technology and Innovation

    Stream three

    STREAM C: Clinical Trials in Oncology

    10 AM

    INSPIRATIONAL KEYNOTE Clinical Operational Excellence: Delivery like an Elite Athlete

    • What is the Athlete Mindset?
    • Parallels between elite sport and clinical trial delivery
    • Applying the athlete-style discipline, goal-setting, ‘pivot quickly’ mindset and performance tracking in delivering complex oncology trials
    • Translating setbacks into learnings and future strengths- The drive for continuous improvement-The perfect race!
    • Sustaining performance and energy across multi-year clinical trials- The Long-Distance Athlete

    Speakers

    Dr Yvette Henry
    Clinical Program Leader ('The Project Runner')

    10:45 AM

    Reserved for Event Sponsor

    • There are many obstacles to running a successful clinical trial – and hospital sites can be one.
    • Slow to set up, delays to patient recruitment, or poor data quality?
    • TCR-Solutions will share some experience and approaches to troubleshooting these challenges.
    • We cannot treat hospital sites like commercial vendors, and we must find a way to work with hospitals to ensure they deliver on time and target.

    11:15 AM

    Morning refreshments and networking

    11:45 AM

    UK Health Policy at a Turning Point: Delivering on the Government’s Life Sciences and 10-Year Cancer Plans

    • Renewed government vision for health, research and life sciences
    • The challenge of moving from strategy to action across the ecosystem
    • Political influences impacting speed, delivery and prioritisation
    • How the sector can push for clarity, consistency and implementation

    Speakers

    Professor Jacob George
    Chief Medical Scientific Officer, MHRA

    12:15 PM

    Reserved for Event Sponsor

    12:45 PM

    Adaptive Oncology Trials: Improving Access and the Patient Perspective

    This session explores how adaptive trial designs are changing oncology research, enabling greater flexibility in trial arms and broader use of therapies across indications. We will discuss what this means for patient access and why embedding patient perspectives early is critical to successful study design and delivery.

    Speakers

    Emma Kinloch
    Patient Advocate and CEO, Salivary Gland Cancer UK

    1:15 PM

    Lunch and networking

    2:15 PM

    PANEL DISCUSSION: Designing Oncology Trials That Work for Every Patient

    • Tackling barriers that limit access and participation for under-represented patient groups.
    • Ensuring cultural relevance, language accessibility and equitable site selection.
    • Embedding PROs and patient insights to shape inclusive eligibility and trial procedures.
    • Measuring what matters: evaluating the impact of patient-centred designs on recruitment and retention.

    Speakers

    Diane Chisholm
    Head of Clinical Operations, Owkin
    Emma Kinloch
    Patient Advocate and CEO, Salivary Gland Cancer UK

    3 PM

    Reserved for Event Sponsor

    3:30 PM

    Afternoon refreshments, networking & Apple prize draw

    4 PM

    Advancing Oncology Clinical Trials in the UK: Navigating the Evolving Regulatory Landscape

    • Implementing MHRA and HRA expectations for innovative oncology trial designs (platform, basket and adaptive studies)
    • Integrating biomarkers, companion diagnostics and expedited pathways within the UK regulatory framework (e.g. ILAP, EAMS)
    • Operationalising UK‑specific approvals: interplay of MHRA, HRA/REC, UK GDPR and local R&D for oncology studies
    • Positioning UK oncology trials in a post‑Brexit environment: alignment with EU/ICH standards and leveraging UK flexibility

    Speakers

    Jacqueline Johnson North
    Founder & CEO, IAOCR & GCSA

    4:30 PM

    PANEL DISCUSSION: Strengthening Patient Recruitment in Oncology Clinical Trials

    • Identifying and addressing key barriers that limit timely and representative recruitment.
    • Improving collaboration between sites, sponsors and patient advocacy groups to expand referral pathways.
    • Enhancing patient trust and understanding through clear, accessible communication strategies.
    • Leveraging AI tools to support more accurate pre-screening, eligibility matching and outreach.

    11:45 AM

    Applying AI Tools Effectively in Clinical Trials

    • Leveraging AI tools to optimize patient recruitment, site selection, and trial feasibility.
    • Using AI for real-time data monitoring, quality checks, and endpoint analysis.
    • Integrating AI solutions seamlessly into trial workflows to support operational efficiency.
    • Ensuring regulatory compliance, validation, and transparency when deploying AI in active studies.

    Speakers

    Olivia Howard
    Associate Director - Clinical Operations, Scancell

    12:15 PM

    Reserved for Event Sponsor

    12:45 PM

    Key regulatory considerations around data quality when using real world data to support clinical trials

    Speakers

    Puja Myles
    Director, Clinical Practice Research Datalink (CPRD), MHRA

    1:15 PM

    Lunch and networking

    2:15 PM

    PANEL DISCUSSION Harnessing Real-World Data and Registries in Clinical Trials: UK & Ireland Perspectives

    • Overview of available RWD sources and disease registries across the UK and Ireland, and how they can support trial design.
    • Leveraging RWD to inform patient eligibility, site selection, and endpoint development.
    • Practical considerations for integrating registry data with trial datasets while ensuring data quality and regulatory compliance.
    • Case studies demonstrating how RWD and registries have accelerated clinical trial insights and improved patient outcomes.

    Speakers

    Puja Myles
    Director, Clinical Practice Research Datalink (CPRD), MHRA
    Myles Dakin
    Chairman & Founder, Hypo-Stream

    3 PM

    Reserved for Event Sponsor

    3:30 PM

    Afternoon refreshments, networking & Apple prize draw

    4 PM

    Regulatory landscape for AI & Software in UK & Ireland

    A concise overview of how AI and software-based medical technologies are regulated across England and Ireland, highlighting alignment, divergence, and what developers and trial teams need to plan for now.

    Speakers

    Surbhi Gupta
    Advisor to National AI team, NHS England

    4:30 PM

    PANEL DISCUSSION Future of Clinical Trial Professionals: How Technology Is Transforming Workforce Roles and Expectations

    • Reimagining responsibilities across clinical trial functions in an AI- and automation-driven environment
    • Evolving from task-based roles to strategic, insight-driven contributors across operations and data functions
    • Redefining entry-level roles as technology reshapes foundational skills, expectations, and career pathways
    • Identifying the new capabilities required to ensure technology enhances, not replaces the expertise of clinical trial professionals

    Speakers

    Catherine Mela
    Head Precision Medicine Operations, GSK
    Blanka Hezelova
    Associate Director, Precision Medicine Scientific Operations, Bioethics Coach, GSK
    Jacqueline Johnson North
    Founder & CEO, IAOCR & GCSA

    5 PM

    Chairperson’s closing remarks

    Speakers

    Catherine Mela
    Head Precision Medicine Operations, GSK

    7:30 AM

    Registration and refreshments

    8:30 AM

    GlobalData Opening Remarks – State of The UK Clinical Trials Industry – Strategic Intelligence

    Speakers

    Dr Julie Munch Khan
    Chief Commercial Officer, Deallus

    9 AM

    OPENING KEYNOTE: Clinical Trials in the UK: A Cross-Sector Approach To Making The UK A Destination For Clinical Research

    • Government priorities: two years on
    • How organisations across the sector are working together to continually improve the system
    • What makes the UK a destination for clinical trials
    • Looking ahead

    Speakers

    Prof. Lucy Chappell
    Chief Scientific Adviser, Department of Health and Social Care, Chief Executive Officer, National Institute of Health Research (NIHR)

    9:30 AM

    Reserved for Event Sponsor

    10 AM

    KEYNOTE PANEL UK Clinical Trials at a Crossroads: Pricing, Investment and Performance Challenges

    • How pricing frameworks like VPAG are influencing pharma exit decisions
    • Consequences of major R&D pullbacks for the UK research ecosystem
    • Persistent issues: slow approvals, fragmented delivery and rising costs
    • What policy and industry shifts are needed to reverse the trend

    Speakers

    Dr Julie Munch Khan
    Chief Commercial Officer, Deallus
    Alex Churchill
    Deputy Director, Clinical Trials Policy, Department of Health and Social Care
    Dr Suki Balendra
    Director, Strategic Partnerships, Paddington Life Sciences and Director, North West London Clinical Trials Alliance

    10:45 AM

    Reserved for Event Sponsor

    11:15 AM

    Morning refreshments and networking

    11:45 AM

    150 Days to Activation: Can the UK Meet the NIHR’s New Trial Start-Up Standard?

    • What the new national target requires from sites and sponsors
    • Meeting the NIHR’s new FPI targets: 30days for Rare, 60 days for all others
    • Systemic challenges slowing UK clinical trial delivery
    • Enablers: streamlined processes, capacity, and perforMaria Koufali mance management
    • What success looks like for 2025–2026

    Speakers

    Maria Koufali
    Head of UK Vaccine Innovation Pathway, National Institute for Health and Care Research (NIHR)

    12:15 PM

    Reserved for Event Sponsor

    12:45 PM

    Reserved for Eli Lilly

    1:15 PM

    Lunch and networking

    2:15 PM

    PANEL DISCUSSION From Transactional Outsourcing to Strategic Partnership: Aligning Incentives, Expectations, and Execution in Clinical Trials

    • Planning for successful sponsor–vendor relationships
    • Common challenges and pitfalls with vendors and how to address them
    • Improving transparency and alignment across multi-partner trial ecosystems
    • What effective strategic partnership looks like in practice

    Speakers

    Dr. Gaia Kiru
    Head of Operations & Partnerships, Imperial Clinical Trials Unit, Imperial College London
    Jeff Pilot
    Senior Clinical Project Manager, Norgine

    3 PM

    Reserved for Event Sponsor

    3:30 PM

    Afternoon refreshments, networking & Apple prize draw

    4 PM

    Optimising Clinical Trial Feasibility: From Site Selection to Study Design

    • Assessing site capabilities, patient populations, and operational resources to ensure realistic trial execution.
    • Using data-driven approaches and analytics to predict enrollment timelines and potential bottlenecks.
    • Identifying and mitigating risks early to improve study efficiency and reduce delays.
    • Incorporating patient insights and stakeholder feedback to design feasible, patient-friendly protocols.

    Speakers

    Gail Kemp
    Senior Director, Head of Clinical Development Centre UK, Novo Nordisk

    4:30 PM

    PANEL DISCUSSION Maximising Site Productivity: Infrastructure, Burden Reduction and Stronger Output in UK Clinical Trials

    Robust, well supported site infrastructure is the foundation of efficient clinical trial delivery across the UK and Ireland. This session will examine how workforce, facilities, digital systems and governance structures at NHS and HSE sites can be optimised to reduce operational burden and increase throughput of high quality studies. Panellists will share practical strategies for investing in and partnering with sites to strengthen research infrastructure, streamline processes, and enable sustainable growth in commercial and academic trial activity.

    • Assessing current site infrastructure: workforce, facilities, governance and digital capabilities in NHS/HSE settings.
    • Targeted investments and partnerships that meaningfully strengthen site capacity and trial readiness.
    • Aligning sponsor/CRO expectations and processes with real site infrastructure constraints.
    • Building scalable, resilient site infrastructure that supports long term growth in UK & Irish clinical research.

    Speakers

    Dr Julie Munch Khan
    Chief Commercial Officer, Deallus
    Dr. Gaia Kiru
    Head of Operations & Partnerships, Imperial Clinical Trials Unit, Imperial College London

    5 PM

    Chairperson’s closing remarks

    Speakers

    Dr Julie Munch Khan
    Chief Commercial Officer, Deallus

    NETWORKING DRINKS SPONSORED BY XXX

    Streams

    Stream one

    Clinical Operations and Outsourcing

    Stream two

    Clinical Technology and Innovation

    11:45 AM

    FIRESIDE CHAT Risks & Controversies of AI in Clinical Trials

    • Automation bias in practice: Real-world cases show dosing errors occurring when clinicians rely on AI outputs without independent verification.
    • Human oversight failures: Over-reliance on AI, combined with missed pharmacist checks, can directly compromise patient safety.
    • Cognitive deskilling risk: Persistent dependence on AI may erode critical thinking, clinical judgement, and professional expertise over time.
    • Long-term human impact: Growing concern that excessive cognitive offloading to AI could contribute to reduced mental resilience and potential long-term cognitive health risks, highlighting the need for balanced human - AI interaction.

    Speakers

    Puja Myles
    Director, Clinical Practice Research Datalink (CPRD), MHRA
    Jeff Pilot
    Senior Clinical Project Manager, Norgine

    12:15 PM

    Reserved for Event Sponsor

    12:45 PM

    Lunch and networking

    2 PM

    SPOTLIGHT – Innovation in Rare Disease

    • Analysis of Real World (Audit) Data in driving drug discovery
    • Use of RWD in driving drug discovery in rare diseases
    • Leveraging therapeutics for rare disease to larger, multiple global applications

    Speakers

    Myles Dakin
    Chairman & Founder, Hypo-Stream

    2:30 PM

    Reserved for Event Sponsor

    8 AM

    Registration and refreshments

    8:45 AM

    Chairperson’s opening remarks

    Speakers

    Dr Julie Munch Khan
    Chief Commercial Officer, Deallus

    9 AM

    KEYNOTE PRESENTATION: UK regulatory shift – MHRA reforms

    • New UK clinical trials legislation and MHRA processes (combined review, safety reporting, transparency).
    • How global protocols are being adapted (or not) for UK‑specific expectations.
    • How CROs and vendors need to update SOPs, contracting, and timelines.

    Speakers

    James Pound
    Executive Director Innovation and Compliance, MHRA

    9:30 AM

    Reserved for Event Sponsor

    10 AM

    Strength in Collaboration: How Ireland’s Unified Clinical Trial Ecosystem Is Driving Growth and Cross-Border Innovation

    • A Unified National Approach: How Ireland avoids siloed working across research sites, hospitals, regulators and sponsors, and what lessons can be learned from this collaborative ecosystem.
    • Political Momentum & National Structures: Examination of Ireland’s evolving political landscape, including the formation of the National Clinical Trials Oversight Group and the report/recommendations shaping future strategy.
    • Building Attractiveness for Global Sponsors: The concrete steps Ireland is taking, from advisory committees to harmonised processes to make the country more competitive and appealing for commercial and academic clinical trials.
    • Cross-Border Opportunities & UK Alignment: How Ireland and Britain can work together post-Brexit, including expanding trial activity into Northern Ireland and creating a smoother, collaborative pathway across both jurisdictions. We discussed a session around

    Speakers

    Angela Clayton-Lea
    CEO, Cancer Trials Ireland

    10:30 AM

    Reserved for Event Sponsor

    11 AM

    Morning refreshments and networking

    11:45 AM

    PATIENT SPOTLIGHT Upstream Recruitment: Why Representation Is Decided Long Before Consent

    Despite growing commitments to diversity and inclusion in clinical trials, under-representation of marginalised communities persists. Recruitment is often treated as an operational challenge, one that begins at site activation, screening, or consent. This framing overlooks a critical reality: for many communities, clinical trials are never encountered at all.

    Drawing on lived experience and health equity analysis, this talk introduces the concept of upstream recruitment the social, structural, and relational conditions that determine who ever reaches the point of being asked to participate. These include trust in healthcare systems, perceived legitimacy of research, accessibility of trial locations, language and cultural cues, historic harm, and cumulative time and financial burden.

    The session reframes “under-representation” not as passive absence or lack of willingness, but as the predictable outcome of accumulated system signals embedded across healthcare and research ecosystems. By shifting the lens from downstream recruitment tactics to upstream access pathways, this talk invites sponsors, CROs, and trial operators to reconsider where representation is actually won or lost and why equity must be treated as an operating condition, not a late-stage intervention.

    Speakers

    Daniel Newman
    Multi-Award-Winning Patient Engagement Leader & Patient Advocate

    12:15 PM

    Reserved for Event Sponsor

    12:45 PM

    Lunch and networking

    2 PM

    NHS Industry partnerships workings – IHI READI

    Speakers

    Dr Suki Balendra
    Director, Strategic Partnerships, Paddington Life Sciences and Director, North West London Clinical Trials Alliance

    2:30 PM

    Reserved for Event Sponsor

    3 PM

    Afternoon refreshments, networking, and Apple Prize Draw

    3:30 PM

    ROUNDTABLE SESSIONS

    During the roundtable discussion session, the conference hall will be divided into zones. Delegates can choose which zone they would like to join. Each zone will be led by a table lead/host and will focus on a different challenge within the industry. After 30 minutes, delegates will have the opportunity to swap and choose a different table, and each roundtable will run twice.

    ROUNDTABLE 1: Sponsor–CRO Relationships

    Building Strong Sponsor - CRO Partnerships for Efficient Trial Delivery

     

    ROUNDTABLE 2:  Taking the Wheel: Gaining Control of Your eTMF During Active Trials

    Jane Silverwood, Clinical Documental Management Specialist, Owkin

     

    ROUNDTABLE 3: Patient Centricity, Engagement & Retention

    Putting Patients First: Strategies to Recruit, Engage and Retain Participants

     

    ROUNDTABLE 4:   Developing medicines from analysis of real-world data

    Myles Dakin, Chairman & Founder, Hypo-Stream

     

    ROUNDTABLE 5: Reserved for Surbhi Gupta, Advisor to National AI team, NHS England

    Speakers

    Jane Silverwood
    Clinical Documental Management Specialist, Owkin
    Myles Dakin
    Chairman & Founder, Hypo-Stream
    Surbhi Gupta
    Advisor to National AI team, NHS England

    4:30 PM

    Close of conference

    END OF CONFERENCE

    Speakers

    Select a speaker to learn more

    Back
    Alex Churchill
    Deputy Director, Clinical Trials Policy, Department of Health and Social Care

    Session Details:

    KEYNOTE PANEL UK Clinical Trials at a Crossroads: Pricing, Investment and Performance Challenges

    2026-06-09, 10:00 AM

    View In Agenda
    Next speaker
    Back
    Prof. Lucy Chappell
    Chief Scientific Adviser, Department of Health and Social Care, Chief Executive Officer, National Institute of Health Research (NIHR)

    Professor Lucy Chappell FMedSci is the Chief Scientific Adviser for the Department of Health and Social Care (DHSC), with overall responsibility for the department’s research and development, including the National Institute for Health and Care Research (NIHR), the government’s major funder of clinical, public health, social care and translational research.

    Reporting to the Chief Medical Officer, the Chief Scientific Adviser provides science advice and analysis to ministers across the range of health topics and is involved in cross-government science policy.

    Professor Chappell is Professor of Obstetrics at King’s College London, Honorary Consultant Obstetrician at Guy’s and St Thomas’ NHS Foundation Trust and an NIHR Senior Investigator. She will undertake the Chief Scientific Adviser role on secondment into government, while continuing some of her clinical and academic work.

    DHSC Chief Scientific Adviser

    Responsibilities include:

    • overall responsibility for the Department of Health and Social Care’s (DHSC) research policies and budget, including being head of the National Institute for Health and Care Research (NIHR)
    • supporting analysis and evidenced-based decision-making capacity in the department
    • working with Chief Scientific Advisers across government to maximise the impact of science to benefit the UK population

    Session Details:

    OPENING KEYNOTE: Clinical Trials in the UK: A Cross-Sector Approach To Making The UK A Destination For Clinical Research

    2026-06-09, 9:00 AM

    View In Agenda
    Next speaker
    Back
    James Pound
    Executive Director Innovation and Compliance, MHRA

    Session Details:

    KEYNOTE PRESENTATION: UK regulatory shift – MHRA reforms

    2026-06-10, 9:00 AM

    View In Agenda
    Next speaker
    Back
    Professor Jacob George
    Chief Medical Scientific Officer, MHRA

    Session Details:

    UK Health Policy at a Turning Point: Delivering on the Government’s Life Sciences and 10-Year Cancer Plans

    2026-06-09, 11:45 AM

    View In Agenda
    Next speaker
    Back
    Puja Myles
    Director, Clinical Practice Research Datalink (CPRD), MHRA

    Dr Puja Myles is Director of the Medicines and Healthcare products Regulatory Agency’s (MHRA) specialist real world data research service, the Clinical Practice Research Datalink (CPRD). She is a public health specialist and prior to joining CPRD, was a public health academic at the University of Nottingham, UK. She is a fellow of the Faculty of Public Health (UK), a senior fellow of the Higher Education Academy (UK) and has a doctorate in epidemiology. She has been the MHRA’s strategic lead on the development of synthetic data generation approaches and applications since 2017. In addition, she has led on Regulatory Science initiatives including AI explainability, handling concept drift, data quality standards for regulatory purposes, regulatory evidence derived from computer modelling and simulation approaches.

    Session Details:

    Key regulatory considerations around data quality when using real world data to support clinical trials

    2026-06-09, 12:45 PM

    Session Details:

    FIRESIDE CHAT Risks & Controversies of AI in Clinical Trials

    2026-06-10, 11:45 AM

    Session Details:

    PANEL DISCUSSION Harnessing Real-World Data and Registries in Clinical Trials: UK & Ireland Perspectives

    2026-06-09, 2:15 PM

    View In Agenda
    Next speaker
    Back
    Gail Kemp
    Senior Director, Head of Clinical Development Centre UK, Novo Nordisk

    Session Details:

    Optimising Clinical Trial Feasibility: From Site Selection to Study Design

    2026-06-09, 4:00 PM

    View In Agenda
    Next speaker
    Back
    Laura Clifton Hadley
    Head of Clinical Operations, Northern Europe, BMS

    Laura Clifton-Hadley is Head of Clinical Operations, Northern Europe, based in the UK. She leads all clinical trial and late development activities across the Bristol Myers Squibb portfolio. Laura is an experienced leader, with experience in all phases of trials and therapeutic areas. Prior to BMS, she worked as the head of haematology and brain trials at University College London. She has more than 14 years of clinical operations experience, and more than 12 years of line management experience. She sits on various UK and IE industry bodies/government bodies to promote/facilitate commercial clinical research and to ensure that we are bringing the right studies to the UK and IE.
    Laura received her PhD in microbiology from the University of Reading. She also holds an honours degree in microbiology and virology from the University of Warwick.

    Next speaker
    Back
    Stephen Nabarro
    Head of Clinical Operations and Data Management, Cancer Research UK
    Next speaker
    Back
    Dr Julie Munch Khan
    Chief Commercial Officer, Deallus

    Julie is the Chief Commercial Office at Deallus, a market leading strategy consultancy, which was acquired by Global Data  at the beginning of the year. Julie's career in life sciences spans 20 years with a focus on partnering with clients on strategy development on local, regional and global level . For more than decade Julie has led large global and regional competitive mindset training programmes for large pharma. Since 2017 Julie has regularly been engaged as an inspirational speaker on Competitive Mindset across brand, portfolio and corporate audiences. Her expertise includes clinical and commercial planning, brand & portfolio strategy  as well as advising organisation  on personalised healthcare approaches across various disease areas.  Julie holds a PhD in Neuroscience from Imperial College London sponsored by Pfizer.

    Session Details:

    GlobalData Opening Remarks – State of The UK Clinical Trials Industry – Strategic Intelligence

    2026-06-09, 8:30 AM

    Session Details:

    Chairperson’s opening remarks

    2026-06-10, 8:45 AM

    Session Details:

    KEYNOTE PANEL UK Clinical Trials at a Crossroads: Pricing, Investment and Performance Challenges

    2026-06-09, 10:00 AM

    Session Details:

    PANEL DISCUSSION Maximising Site Productivity: Infrastructure, Burden Reduction and Stronger Output in UK Clinical Trials

    2026-06-09, 4:30 PM

    Session Details:

    Chairperson’s closing remarks

    2026-06-09, 5:00 PM

    View In Agenda
    Next speaker
    Back
    Dr Rebecca Clark
    Partner, Principal Investigator, Fylde Coast Clinical Research and Co-Clinical Lead, UK Vaccine Innovation Pathway

    Dr Rebecca Clark is a Partner at Fylde Coast Clinical Research at Layton Medical Centre, a dedicated commercial trials centre in Blackpool. She is a highly experienced trialist with over 70 Phase II/III clinical trials conducted over the last 13 years, with multiple studies as Chief Investigator in the therapy areas of vaccines, obesity medicine, cardiovascular medicine, asthma and diabetes. She holds a number of senior leadership roles including co-clinical lead for the UK Vaccine Innovation Pathway, a UK clinical trials accelerator.

    Fylde Coast Clinical Research at Layton Medical Centre recruits amongst the highest number of commercial participants across the NHS in England and was in the top 1% of NHS recruiting sites when compared with all 637 sites across both primary and secondary care in 22/23. Study participant retention rates exceeded 99%. Her site regularly achieves UK FPV and she is renowned for accelerated set up and recruitment timelines, experience she is now bringing to her role in the UK VIP.

    Fylde Coast Clinical Research currently holds contracts with Eli Lilly, Moderna, Astra Zeneca, Roche, Amgen, Merck, Novo Nordisk and GSK, with whom they are members of the PEER preferred site network.

    Dr Clark continues to be recognised nationally for her excellence in clinical trial delivery, being a former recipient of the Gold Award for Clinical Site of the Year at the Pharmatimes International Clinical Researcher of the Year.

     

    Next speaker
    Back
    Catherine Mela
    Head Precision Medicine Operations, GSK

    Catherine Mela is Executive Director, Head of Precision Medicine Operations, within GSK. In her role, Catherine is accountable for leading the Scientific Operations and Data Operations teams, driving the execution of precision medicine project strategies with efficiency and quality.

    Catherine has gained broad experience in laboratory and bio-sample operations, while leading sampling and laboratory operations teams in AstraZeneca and Roche.

    Prior to working in pharma, Catherine’s background was in Clinical research within the NHS.  She holds a PhD from Imperial College on ‘The impact of treatment strategies on immune responses in HIV-1 infection’.  Catherine is a fellow of the institute of leadership and is passionate about professional development, mentorship and creating a supportive environment for individuals within her teams.

    Session Details:

    PANEL DISCUSSION Future of Clinical Trial Professionals: How Technology Is Transforming Workforce Roles and Expectations

    2026-06-09, 4:30 PM

    Session Details:

    Chairperson’s closing remarks

    2026-06-09, 5:00 PM

    View In Agenda
    Next speaker
    Back
    Blanka Hezelova
    Associate Director, Precision Medicine Scientific Operations, Bioethics Coach, GSK

    Blanka is an Associate Director within Precision Medicine Scientific Operations at GSK with over ten years of experience in research spanning from clinical site to sponsor roles, and expertise in biosample operations. She leads operational aspects of trials with a focus on innovation and excellence, successfully managing complex clinical studies while ensuring compliance and participant protection. Herf passion lies in ethical research and strategic improvements for operational efficiency.

    Session Details:

    PANEL DISCUSSION Future of Clinical Trial Professionals: How Technology Is Transforming Workforce Roles and Expectations

    2026-06-09, 4:30 PM

    View In Agenda
    Next speaker
    Back
    Jacqueline Johnson North
    Founder & CEO, IAOCR & GCSA

    Facilitating connections and working with global industry leaders, parliamentarians and key opinion leaders to pioneer globally consistent best practices standards for clinical research.

    Session Details:

    Advancing Oncology Clinical Trials in the UK: Navigating the Evolving Regulatory Landscape

    2026-06-09, 4:00 PM

    Session Details:

    PANEL DISCUSSION Future of Clinical Trial Professionals: How Technology Is Transforming Workforce Roles and Expectations

    2026-06-09, 4:30 PM

    View In Agenda
    Next speaker
    Back
    Jeff Pilot
    Senior Clinical Project Manager, Norgine

    Session Details:

    FIRESIDE CHAT Risks & Controversies of AI in Clinical Trials

    2026-06-10, 11:45 AM

    Session Details:

    PANEL DISCUSSION From Transactional Outsourcing to Strategic Partnership: Aligning Incentives, Expectations, and Execution in Clinical Trials

    2026-06-09, 2:15 PM

    View In Agenda
    Next speaker
    Back
    Emma Kinloch
    Patient Advocate and CEO, Salivary Gland Cancer UK

    Session Details:

    PANEL DISCUSSION: Designing Oncology Trials That Work for Every Patient

    2026-06-09, 2:15 PM

    Session Details:

    Adaptive Oncology Trials: Improving Access and the Patient Perspective

    2026-06-09, 12:45 PM

    View In Agenda
    Next speaker
    Back
    Myles Dakin
    Chairman & Founder, Hypo-Stream

    Myles Dakin founded the research company, Hypo-Stream, to address anticipated needs in burns treatment and nosocomial infection with AMR pathogens.  His R&D journey has led to discovery of a multi-modal anti-inflammatory agent that neutralises both Il-6 and TNF-a alongside altering the ratio of Il-10 to Il-6 in a favourable way.  Hypo-Stream has progressed to an emerging pharma company with CHMP supported Ph III ready asset and orphan designation in a rare disease alongside a pipeline with potential global impact.

    Session Details:

    SPOTLIGHT – Innovation in Rare Disease

    2026-06-10, 2:00 PM

    Session Details:

    ROUNDTABLE SESSIONS

    2026-06-10, 3:30 PM

    Session Details:

    PANEL DISCUSSION Harnessing Real-World Data and Registries in Clinical Trials: UK & Ireland Perspectives

    2026-06-09, 2:15 PM

    View In Agenda
    Next speaker
    Back
    Surbhi Gupta
    Advisor to National AI team, NHS England

    Session Details:

    ROUNDTABLE SESSIONS

    2026-06-10, 3:30 PM

    Session Details:

    Regulatory landscape for AI & Software in UK & Ireland

    2026-06-09, 4:00 PM

    View In Agenda
    Next speaker
    Back
    Dr. Gaia Kiru
    Head of Operations & Partnerships, Imperial Clinical Trials Unit, Imperial College London

    Dr Gaia Kiru is Head of Operations and Partnerships at ICTU-Global, part of the Imperial Clinical Trials Unit (ICTU) at Imperial College London, where she leads strategic collaboration with industry to design and deliver high-impact, clinically relevant, clinical trials and studies. With 20 years’ experience across industry, the NHS, and academia, she works at the intersection of sponsors, CROs, academic partners and NHS sites to strengthen trial delivery models and improve alignment between strategy and execution across diverse settings and therapeutic areas.

    Session Details:

    PANEL DISCUSSION From Transactional Outsourcing to Strategic Partnership: Aligning Incentives, Expectations, and Execution in Clinical Trials

    2026-06-09, 2:15 PM

    Session Details:

    PANEL DISCUSSION Maximising Site Productivity: Infrastructure, Burden Reduction and Stronger Output in UK Clinical Trials

    2026-06-09, 4:30 PM

    View In Agenda
    Next speaker
    Back
    Olivia Howard
    Associate Director - Clinical Operations, Scancell

    Leading the Quality and Process optimisation of Clinical Operations, alongside the strategic planning and data-driven development of oncology clinical trial pipelines, their experience spans trial management, clinical monitoring, pharmacovigilance and medical writing, gained across both UK Biotech and Global Pharmaceutical organisations. Committed to advancing risk-based strategies, scalable and efficient operations, and GCP compliance through thoughtful innovation.

    Session Details:

    Applying AI Tools Effectively in Clinical Trials

    2026-06-09, 11:45 AM

    View In Agenda
    Next speaker
    Back
    Dr Suki Balendra
    Director, Strategic Partnerships, Paddington Life Sciences and Director, North West London Clinical Trials Alliance

    Suki Balendra a senior leader in the NHS with a 20-year background in facilitating, growing, and promoting health research in the U.K.  She has substantial, in-depth experience across sectors including industry, academia, NHS, and central government.

    She is currently the Director of Strategic Partnerships for Imperial College Healthcare NHS Trust in Northwest London. She leads the strategic work with the Life sciences industry in the region with an emphasis on a new life sciences cluster in Paddington. Suki created and leads the North West London Clinical Trials Alliance. She started her career in the Biotechnology Industry at Abbott Diagnostics Ltd. Within a Good manufacturing practice (GMP) environment she worked on several operational projects to improve efficiency, cost, and reproducibility.

    In 2018 she was seconded to the Office of Life Sciences within the Department of Business and Industrial Strategy. where she attracted and negotiated new business to increase the UK’s market share of health and care research activity. During the pandemic she provided operational leadership to the NHS covid vaccine research response in Northwest London.

    Suki has PhD from the University of Warwick, and she is accredited to black belt in Lean Six Sigma. She is a passionate advocate for UK PLC as the number one destination to conduct clinical trials.

    Session Details:

    NHS Industry partnerships workings – IHI READI

    2026-06-10, 2:00 PM

    Session Details:

    KEYNOTE PANEL UK Clinical Trials at a Crossroads: Pricing, Investment and Performance Challenges

    2026-06-09, 10:00 AM

    View In Agenda
    Next speaker
    Back
    Dr Yvette Henry
    Clinical Program Leader ('The Project Runner')

    Session Details:

    INSPIRATIONAL KEYNOTE Clinical Operational Excellence: Delivery like an Elite Athlete

    2026-06-09, 10:00 AM

    View In Agenda
    Next speaker
    Back
    Angela Clayton-Lea
    CEO, Cancer Trials Ireland

    Session Details:

    Strength in Collaboration: How Ireland’s Unified Clinical Trial Ecosystem Is Driving Growth and Cross-Border Innovation

    2026-06-10, 10:00 AM

    View In Agenda
    Next speaker
    Back
    Jane Silverwood
    Clinical Documental Management Specialist, Owkin

    Session Details:

    ROUNDTABLE SESSIONS

    2026-06-10, 3:30 PM

    View In Agenda
    Next speaker

    Advisory Board

    Select a member to learn more

    Back
    Dr Alison McMorn
    PH.D – VP, CLINICAL DEVELOPMENT, AMO PHARMA LTD

    Dr. McMorn is an experienced clinical development researcher with over 25 years of industry experience and has a strong focus in CNS and paediatric drug development. She has worked for both Pharmaceutical Companies and Contract Research Organisations including holding positions at SAR Monitoring Services Ltd, Mundipharma International Ltd and Shire Development Inc. Starting her career at SAR as a Clinical Research Associate (CRA) she subsequently moved to Mundipharma where she was responsible for initiating the first paediatric clinical research program for the company. At Shire Dr. McMorn led, planned and managed global paediatric and adult clinical development programs for a wide variety of indications including psychiatry, pain, gastrointestinal and hepatology across all phases of development (Phase 0 to Phase 4). In addition she was responsible for harmonizing Clinical Trial Administrator (CTA) working practices across all regions for the company. In 2015 Dr. McMorn joined AMO Pharma Ltd, a virtual pharmaceutical company focused predominantly on paediatric neurodevelopmental rare diseases, as VP of Clinical Development. She holds an undergraduate degree in Pharmacology and a PhD in Psychology from the University of Leeds, UK.

    Next
    Back
    Behtash Bahador
    Senior Director, Community Engagement & Partnerships, CISCRP

    Behtash Bahador is the Senior Director of Community Engagement & Partnerships at the non-profit organization CISCRP, and holds a Master of Science in Health Communication from the Tufts University School of Medicine. Since 2014, he has collaborated with a range of stakeholder groups to establish and implement patient- and public-centric initiatives across the life-cycle of drug and treatment development. This has included supporting the development of regulatory and cross-disciplinary best practice guidelines, operationalizing key elements of evidence-based public health programing into research engagement activities, and always keeping the needs of patients, participants and the public at the forefront of his work.

    Next
    Back
    Kathleen Cohen
    Vice President, Clinical Development, Marinus Pharmaceuticals

    Kathleen Frenia Cohen is Vice President and Head of Clinical Development Operations at Marinus Pharmaceuticals.  Prior to joining Marinus, she spent 20+ years at PRA Health Sciences in a variety of project management and operational oversite roles. Kathleen graduated from the University of the Science in Philadelphia with a PharmD and completed a post-doctoral fellowship in Pharmacoeconomics and Outcomes Research from Rutgers College of Pharmacy. Kathleen resides in Media, PA.

    Next
    Back
    Aditya Kotta
    Head of Business Development, Novotech

    Aditya is the Regional Director of Business Development at Novotech, the Asia Pacific specialist CRO. He has extensive experience helping sponsor companies make their trials a reality across a range of projects from first in human to phase iv.

    Next
    Back
    Martin Rodriguez
    Consumer Safety & Evidence Global Quality & Excellence Head, Sanofi

    Senior executive Leader in Life Science (Biochemist) and Lean/Six Sigma Green-belt certified, with more than 20 year of experience in clinical operations, Operational Excellence (i.e., operational strategy, performance management, process optimization, risk management, Quality-by-Design and team performance), clinical quality, and Service Providers / Outsourcing management.

    I developed, reengineered, automated, and optimized business processes with a risk-based and approach to produce high quality outputs and to ensure regulatory compliance. I led the development, implementation and monitoring of different operational and quality strategies and models including Outsourcing as well as new/ innovative clinical capabilities to fulfill consumers/ patients needs .

    Next
    Back
    Rosalie Filling
    Vice President, Senior Global Head R&D Operations, Endo Pharmaceuticals

    In her over 25 years of experience, Rosalie “Rosie” Filling has transformed R&D operations in every company she has worked for, developing clear-cut strategies to help advance clinical trials with high-quality operational execution and scientific excellence.

     

    Rosie is the Vice President, Senior Global Head R&D Operations Endo International plc. She is part of the global R&D leadership team and is charged with the coordination and implementation of clinical development strategies for the company’s research and development. She provides strategic direction and oversight of the R&D Operations team, which includes clinical operations, data management, biostatistics, medical writing, clinical supplies, trial master file/inspection readiness and business operations. This integrated team handles the execution of all aspects related to Endo’s clinical trials. Endo has active research and development programs in men’s health, orthopedics, and endocrinology. Beyond these therapeutic areas, the company also has focused development in the areas of sterile injectables and complex generic products.

     

    Rosie’s main focus at all times is on the end users—the patients. Bringing new and, at times, life-saving medications to patients drives Rosie’s sense of purpose.

     

    Rosie joined Endo from Lupin Pharmaceuticals in Blue Bell, PA where she was Senior Director, Head of Clinical Operations, and built the clinical operations organization to support the US and Global R&D Organization. Prior to Lupin, Rosie spent nearly five years at Teva in Frazer, PA where she was the US site head of Clinical Operations and was responsible for the successful delivery of Inhalation, Women’s Health, and Cardiovascular clinical trials. Earlier in her career, Rosie held various roles at Eisai, MGI Pharma and PPD.

     

    Rosie earned her B.S. in Biology with a minor in Chemistry from the University of Pittsburgh.

    Next
    Back
    Edwin van Vulpen
    Executive Director and Head of Clinical Business Development Euro-Asia
    Next

    Plan Your Visit

    Venue

    Hilton Park Lane, London, UK We have partnered with exhibition accommodation experts, HotelMap, to secure discounted hotels for our visitors and exhibitors. Click on the link to find the best rates available. The HotelMap Assistance team are available 24 hours a day 7 days a week to support you with your hotel booking.

    Accommodation

    Arena International Events Group “(Arena”) is aware of numerous third-party agencies which are contacting Arena’s customers and purporting to have access to hotel room bookings, events attendee lists and selling unsolicited services. It is unclear whether the agencies in question are in possession of such information, or whether they intend to scam unsuspecting customers. Whilst Arena International Events Group pursues such third-party companies for their potentially illicit activity, Arena encourages you to be cautious in engaging with such third-party agencies and Arena shall not accept any responsibility for any losses incurred by you should you choose to engage with third parties that have no affiliation to Arena International Events Group..

    2026 Sponsors

    Select a sponsor to learn more

    FEATURED SPONSORS

    SESSION SPONSORS

    TECHNOLOGY SHOWCASE SPONSORS

    DRINKS RECEPTION SPONSOR

    Prize Draw Sponsor

    EXHIBITORS

    Co-Sponsor

    Why partner?

    Contact us to become a partner

    Partnership Opportunities

    We work with you to design a bespoke package to meet your business needs, where you could:

    • Demonstrate your expertise on the agenda – have the attention of the entire audience. For greatest impact, why not position your talk before a networking break and immediately conduct follow up conversations with highly engaged attendees
    • Showcase your business and its services at an exhibition booth, which provides a perfect meeting place for prospective new clients
      Present the value proposition of your offering over your competitors, in front of an audience of active, engaged potential customers
    • Speak with key decision makers as part of our intimate, interactive roundtable style workshop sessions with over 8 hours allowed for networking

    Event reach

    • 200+ attendees each year
    • 80% attendees C-suite level

     

    Take a look at our current sponsors

    Resources

           
           
       

    Media Centre

    Become A Media Partner

    See What It's All About

    Enquiry

    Contact Us

    SPONSORSHIP ENQUIRIES

    Ben Lloyd-Davis

    Head of Healthcare Sponsorship

    +44 207866 9497

    SPEAKING OPPORTUNITIES

    Maya Hudson

    Head of Production

    +44 204540 7766

    MARKETING ENQUIRIES

    Hattie Dean

    Marketing Manager

    DELEGATE ENQUIRIES

    Sunny Saikia

    VIP Delegate Manager

    SPONSORSHIP ENQUIRIES

    To enquire about sponsorship opportunities for the conference, please contact:

    Ben Lloyd-Davis

    Head of Healthcare Sponsorship


    +44 207866 9497

    SPEAKER ENQUIRIES

    To enquire about speaking opportunities for the conference, please contact:

    Maya Hudson

    Head of Production


    +44 204540 7766